Phase I
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
Even with the holidays among us, there were a number of clinical trial announcements. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
AB Science SA reported promising data from its Phase IIb/III trial of masitinib in patients with confirmed mild to moderate Alzheimer’s disease.
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19.
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
Regeneron Pharmaceuticals reported that it is pausing enrollment in two of its clinical trials for odronextamab for lymphoma. The U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the trials.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
PRESS RELEASES